scispace - formally typeset
A

Andrew J. Lotery

Researcher at University of Southampton

Publications -  404
Citations -  20324

Andrew J. Lotery is an academic researcher from University of Southampton. The author has contributed to research in topics: Macular degeneration & Medicine. The author has an hindex of 64, co-authored 358 publications receiving 16739 citations. Previous affiliations of Andrew J. Lotery include Netherlands Institute for Neuroscience & University of Iowa.

Papers
More filters
Journal ArticleDOI

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

Heribert Schunkert, +166 more
- 01 Apr 2011 - 
TL;DR: This paper performed a meta-analysis of 14 genome-wide association studies of coronary artery disease (CAD) comprising 22,233 individuals with CAD (cases) and 64,762 controls of European descent followed by genotyping of top association signals in 56,682 additional individuals.
Journal ArticleDOI

A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants

Lars G. Fritsche, +185 more
- 01 Feb 2016 - 
TL;DR: The results support the hypothesis that rare coding variants can pinpoint causal genes within known genetic loci and illustrate that applying the approach systematically to detect new loci requires extremely large sample sizes.
Journal ArticleDOI

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

TL;DR: The comparison of visual acuity at 1 year between bevacizumab and ranibizumabs was inconclusive, and other outcomes are consistent with the drugs and treatment regimens having similar efficacy and safety.
Journal ArticleDOI

Seven new loci associated with age-related macular degeneration

Lars G. Fritsche, +185 more
- 01 Apr 2013 - 
TL;DR: A collaborative genome-wide association study, including >17,100 advanced AMD cases and >60,000 controls of European and Asian ancestry, identifies 19 loci associated at P < 5 × 10−8, which show enrichment for genes involved in the regulation of complement activity, lipid metabolism, extracellular matrix remodeling and angiogenesis.
Journal ArticleDOI

Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial

TL;DR: The initial results of this retinal gene therapy trial are consistent with improved rod and cone function that overcome any negative effects of retinal detachment, and lend support to further assessment of gene therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which intervention should ideally be applied before the onset ofretinal thinning.